1. Aamdal S, Hallen MN, Tonclli D, Lauvvang G, Owre K, Hatlcvoll R (1998) Docetaxel (Taxotere) combined with radiation in locally advanced non-small cell lung cancer: A phase I/II study. Proc ASCO 17: 476a (abstr. 1830).
2. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of Gemcitabine in non-small cell lung cancer. A phase II study. J Clin Oncol: 12, 1535–1540.
3. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive stage non-small cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9: 1618–1626.
4. Albain KS, Rush VW, Crowley JJ, Rice TW, Turrisi III AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, Fosmire H, Taylor SA, Stelzer KJ, Beasley KR, Livingston RB (1995) Concurrent Cisplatin/Etoposide plus chest radiotherapy followed by surgery for stage IIIA (N2) and IIIB non-small cell lung cancer: Major results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13: 1880–1892.
5. Anderson H, Cottier B, Nicolson M, Milroy R, Maughan T, Bond M, Falk S, Burt B, Carmichael J, Thatcher N (1997) Phase III study of Gemcitabine versus best supportive care in advanced non-small cell lung cancer. Lung Cancer 18(suppl. 1): 9 (abstr.).